Precision Neuroscience Raised $250 Million in Series D

The medical technology firm reached a valuation exceeding $1 billion following a new investment round.

Updated on Sept. 24, 2026 in Alzheimer’s

Precision Neuroscience Raised $250 Million in Series D

Live Poll

Do you support significant private investment in brain-computer interface technology?

Precision Neuroscience secured $250 million in Series D funding, pushing the company's valuation past the $1 billion mark. The capital infusion follows significant progress for its neural implant technology, which aims to provide a less invasive alternative to traditional deep-brain probes.

Why it matters

Investors are backing the company due to its less invasive approach to brain-computer interfaces compared to existing deep-brain probes. The funding will support the development of permanent implant solutions, a process the company notes will take several years to reach regulatory approval.

The company has performed over 100 procedures across 18 medical centers using its electrode-laden thin film technology. The FDA cleared the Layer 7 device in April 2025 for up to 30 days of clinical use.

The players

Precision Neuroscience

This neurotechnology company is headquartered in New York and focuses on developing less invasive brain-computer interface devices.

Pershing Square

This investment management firm contributed to the funding round alongside the Ackman Oxman Institute.

Ackman Oxman Institute

Based in Manhattan, this institution supports medical and scientific research initiatives.

The details

The technology centers on a thin film embedded with 1,024 electrodes that rests on the surface of the brain. Precision Neuroscience maintains its own manufacturing operations for these electrode arrays in Texas to support its ongoing clinical work.

Precision Neuroscience was founded in 2021.
The FDA granted clearance for the Layer 7 device in April 2025.
The company announced the Series D funding in September 2026.

The Big Picture

This funding extension follows the FDA clearance of the Layer 7 device and builds on the clinical data gathered from over 100 procedures. It marks a significant financial step forward in the company's efforts to transition from temporary to permanent neural implant technologies.

The development of less invasive neural implants could eventually offer new treatment options for patients with complex neurological conditions. While the technology is currently cleared for limited-duration use, successful regulatory milestones for permanent implants would shift the available clinical standards for brain-related medical care.

The takeaway

The move toward less invasive brain-computer interfaces represents a major shift in how researchers approach long-term neurological monitoring. Readers should note that while this funding accelerates the company's research, permanent implant solutions remain years away from general clinical availability.